2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Bibliografski detalji
Format:	Članak
Jezik:	English
Izdano:	Korean Association for the Study of the Liver 2018-09-01
Serija:	Clinical and Molecular Hepatology
Teme:	Chronic hepatitis C Treatment Direct acting antivirals Guidelines
Online pristup:	http://e-cmh.org/upload/pdf/cmh-2018-1004.pdf

Slični predmeti

KASL clinical practice guidelines: Management of Hepatitis C
Izdano: (2014-06-01)

KASL clinical practice guidelines for management of chronic hepatitis B
Izdano: (2019-06-01)

KASL clinical practice guidelines for management of chronic hepatitis B
Izdano: (2022-04-01)

KASL Clinical Practice Guidelines: Management of chronic hepatitis B
Izdano: (2012-06-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
od: Özlem KANDEMİR
Izdano: (2018-12-01)

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
od: Jong Eun Yeon
Izdano: (2018-09-01)

KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Izdano: (2023-07-01)

New drugs in the treatment of chronic hepatitis C
od: R. Jimenez Galan, i dr.
Izdano: (2014-04-01)

Current Treatment Of Chronıc Hepatıtıs C Genotype 1
od: Mesut Aydın, i dr.
Izdano: (2018-10-01)

Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? – Indications for Treatment
od: Kyung-Ah Kim
Izdano: (2016-03-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
od: Chung-Feng Huang, i dr.
Izdano: (2020-07-01)

2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What’s Different?
od: Ji Hoon Kim
Izdano: (2019-03-01)

Hepatitis C Treatment: A Review and Update
od: Jelena Jakab, i dr.
Izdano: (2017-04-01)

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
od: Yuri Cho, i dr.
Izdano: (2015-12-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
od: Soon Young Ko, i dr.
Izdano: (2018-12-01)

Hepatitis C Virus Infection in Europe
od: Margarida Simão, i dr.
Izdano: (2024-09-01)

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C
od: Jessica Ramsay, i dr.
Izdano: (2020-10-01)

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D
od: Nauman Kashif, i dr.
Izdano: (2020-08-01)

Sofosbuvir and Ribavirin in Chronic Hepatitis C Virus Patients with No Response or Relapse with Interferon Therapy
od: Shaimuna Fareeha Sajjad, i dr.
Izdano: (2020-12-01)

High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam
od: Thong Duy Vo, i dr.
Izdano: (2024-10-01)

New treatment of hepatitis C (Direct Acting Antiviral)
od: Mohsen Akhondi-Meybodi
Izdano: (2019-10-01)

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
od: Christer F. Aas, i dr.
Izdano: (2020-06-01)

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
od: A. I. Gubenko, i dr.
Izdano: (2023-12-01)

Antiviral therapy in chronic hepatitis C virus infection
od: Irina Russu
Izdano: (2019-09-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
od: Christopher Dietz, i dr.
Izdano: (2022-06-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
od: Paweł Pabjan, i dr.
Izdano: (2022-01-01)

Problematic issues of the effectiveness of treatment of patients with chronic viral hepatitis C according to the State program and the ways of their solution.
od: L. R. Shostakovych-Koretska, i dr.
Izdano: (2018-11-01)

Hepatitis C treatment: where are we now?
od: Burstow NJ, i dr.
Izdano: (2017-02-01)

Cost-effectiveness of treating hepatitis C in Seychelles
od: Naomi Joan Faray Adeline, i dr.
Izdano: (2019-05-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
od: Cassia Leal, i dr.
Izdano: (2023-01-01)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
od: Ken Sato, i dr.
Izdano: (2022-04-01)

Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
od: Ghaydaa A. Shehata, i dr.
Izdano: (2022-12-01)

Emerging Therapies for Hepatitis C
Izdano: (2014-09-01)

Chronic hepatitis C virus infection: An internist’s opinion (Part 1)
od: M L Zubkin, i dr.
Izdano: (2016-10-01)

Hepatitis C in Children—An Asia–Pacific Concise Perspective
od: Lynette Goh, i dr.
Izdano: (2024-10-01)

The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis
od: Na He, i dr.
Izdano: (2022-07-01)

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
od: Xinyu Du, i dr.
Izdano: (2023-03-01)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
od: Heidar Sharafi, i dr.
Izdano: (2020-01-01)

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
od: Diana Valutite, i dr.
Izdano: (2022-04-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
od: Byung Soo Kwan, i dr.
Izdano: (2021-03-01)